Table 2.
Response to 90Y-ibritumomab tiuxetan and 131I-tositumomab in relapsed/refractory low- to intermediate-grade NHL
| Investigator | Patients/Prior Therapy | Percent CR | Percent PR |
| 90Y-ibritumomab tiuxetan | |||
| Knox 199622 | 18/+ | 34 | 38 |
| Witzig 199923 | 51/+ | 26 | 41 |
| Witzig 200224 | 57/+ | 15 | 59 |
| Witzig 200225 | 143/+ | 30 | 50 |
| 131I-tositumomab | |||
| Kaminski 200019 | 59/+ | 34 | 36 |
| Vose 200020 | 47/+ | 32 | 25 |
| Kaminski 200121 | 60/+ | 20 | 45 |
CR, complete response; PR, partial response; +, received prior therapy